Global Dermatology Partnering 2015-2022: Deal trends, players and financials

$3,495.00

The Global Dermatology Partnering 2015-2022 report provides comprehensive understanding and unprecedented access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies

Publication date
April 2022
Number of pages
450+
Product type
Therapy profile
Available formats
PDF document
Report edition
3
SKU
CP2216

The Global Dermatology Partnering 2015-2022: Deal trends, players and financials report provides an understanding and access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in Dermatology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Dermatology partnering agreement structure
  • Dermatology partnering contract documents
  • Top Dermatology deals by value
  • Most active Dermatology dealmakers

 

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

 

The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dermatology deals.

 

The report presents financial deal terms values for Dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

 

The initial chapters of this report provide an orientation of dermatology dealmaking trends.

 

Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in dermatology dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

 

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

 

Chapter 4 provides a review of the leading dermatology deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active dermatology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 5 provides comprehensive access to dermatology deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all dermatology partnering deals by specific dermatology target announced since 2015. The chapter is organized by specific dermatology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2015.      

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

Report scope

 

Global Dermatology Partnering 2015-2022 is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.

 

Global Dermatology Partnering 2015-2022 includes:

 

  • Trends in dermatology dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access tohundreds of dermatology deal contract documents
  • Access to dermatology deal records
  • The leading dermatology deals by value since 2015
  • Most active dermatology dealmakers since 2015

 


The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.

 

In Global Dermatology Partnering 2015-2022, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Dermatology Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for dermatology deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Dermatology Partnering 2015 to 2022 provides the reader with the following key benefits:

 

  • In-depth understanding of dental deal trends since 2015
  • Access dermatology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between dermatology partner companies
  • Comprehensive access to links to actual dermatology deals entered into by the world’s biopharma companies
  • Indepth review of dermatology deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner dermatology opportunities
  • Uncover companies actively partnering dermatology opportunities

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Dermatology dealmaking

 

2.1. Introduction

2.2. Dermatology partnering over the years        

2.3. Dermatology partnering by deal type

2.4. Dermatology partnering by industry sector

2.5. Dermatology partnering by stage of development

2.6. Dermatology partnering by technology type

2.7. Dermatology partnering by therapeutic indication

 

Chapter 3 –Financial deal terms for Dermatology partnering

 

3.1. Introduction

3.2. Disclosed financials terms for Dermatology partnering

3.3. Dermatology partnering headline values

3.4. Dermatology deal upfront payments

3.5. Dermatology deal milestone payments

3.6. Dermatology royalty rates

 

Chapter 4 – Leading Dermatology deals and dealmakers

 

4.1. Introduction

4.2. Most active in Dermatology partnering

4.3. List of most active dealmakers in Dermatology       

4.4. Top Dermatology deals by value

 

Chapter 5 – Dermatology contract document directory

                                            

5.1. Introduction

5.2. Dermatology partnering deals where contract document available

 

Chapter 6 – Dermatology dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by Dermatology therapeutic target

 

Appendices

 

Appendix 1 – Directory of Dermatology deals by company A-Z since 2015

Appendix 2 – Directory of Dermatology deals by deal type since 2015

Appendix 3 – Directory of Dermatology deals by stage of development since 2015

Appendix 4 – Directory of Dermatology deals by technology type since 2015

Further reading on dealmaking

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Dermatology partnering since 2015

Figure 2: Dermatology partnering by deal type since 2015

Figure 3: Dermatology partnering by industry sector since 2015

Figure 4: Dermatology partnering by stage of development since 2015

Figure 5: Dermatology partnering by technology type since 2015

Figure 6: Dermatology partnering by indication since 2015

Figure 7: Dermatology deals with a headline value

Figure 8: Dermatology deals with upfront payment values

Figure 9: Dermatology deals with milestone payment

Figure 10: Dermatology deals with royalty rates

Figure 11: Active Dermatology dealmaking activity since 2015

Figure 12: Top Dermatology deals by value since 2015

 

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3Derm Systems, 3D Systems, 23andMe, Abacus Health Products, Abbvie, ABIGO Medical, Ablexis, Accelis Pharma, AccuTec Blades, Acelity, Acell, Acino Pharma, Aclaris Therapeutics, Actelion, Adhesys Medical, adMare BioInnovations, Advanced Human Imaging, Advanced Medical Solutions, Advanz Pharma, Advonex, Aesthetic Management Partners, Aesthetic Solutions, AFT Pharmaceuticals, Aghraas-Cigalah, AiCuris, Air Force Research Laboratory, AiVita Biomedical, Ajinomoto Bio-Pharma Services, Akaal Pharma, ALASTIN Skincare, Alat Medika Indonesia, Albany Molecular Research, Alibaba Health, AlivaMab Discovery Services, ALK-Abello, Allderma, Allergan, Allergan (name changed from Actavis), Allergan Aesthetics, Alliance Pharma, Alliqua Biomedical, AlloSource, Almirall, Alpha Pharma, Altaris Capital Partners, Altrazeal Trading, Alvotech, American Academy of Professional Coders, American Medical Technologies, American Skin Association, Amgen, AMI, AMNIOX, Amor (Suzhou) Medical Sci-Tech, AMSilk, Amyris, Anacor Pharmaceuticals, ANANDA Scientific, Angelini Pharma, AnGes MG, Angionetics, Anhalt University of Applied Sciences, ANI Pharmaceuticals, Anlicare International, Antares Pharma, Anterios, Antibe Therapeutics, AntibioTx, AOTI, Aphex BioCleanse Systems, APL, Applied Biology, APR Applied Pharma Research, Apria Healthcare Group, Aqua Pharmaceuticals, Aquavit Pharmaceuticals, Aralez Pharmaceuticals, Arch Biopartners, Arch Therapeutics, Arcutis Biotherapeutics, arGEN-X, argenx, Arjo, Arrevus, Arrien Pharmaceuticals, Arsenal Medical, Arthrex, Art of Technology, Asia Green Biotechnology, Aslan Pharma, Assertio Therapeutics, Astellas Pharma, Astion Pharma, AstraZeneca, ATG Allied Technologies, Athenex, Atropos Therapeutics, Aucta Pharmaceuticals, Aurealis Therapeutics, Avalon Pharmaceuticals, Avaria Health & Beauty, Avicanna, AVIR Pharma, Avita Medical MENA, Avita Therapeutics, AvKARE, Avra, Axcelon Dermacare, Axonlab, Axxess Pharma, Azitra, Back-A-Line, Bandgrip, BASF, Basilea Pharmaceutica, Bassett Salon Solutions, Bausch & Lomb, Bavarian Ministry for Economic Affairs and Media, Energy and Technology, Baxalta, Bayer, Baylor Research Institute, Beiersdorf, Beijing InnoCare Pharma, Bellus Health, Ben-Gurion University, Berkshire Sterile Manufacturing, Berlin-Brandenburg Center for Regenerative Therapies, Berlin Chemie, Best Choice, BGN Technologies, Bill and Melinda Gates Foundation, Bio-Gate, BioAesthetics, Biocogent, Biocon, BioCryst Pharmaceuticals, BioDerm, Biogen, Biohaven Pharmaceutical, BioLab Sciences, Biomedical Advanced Research and Development Authority, BIOMEDX Group, BioMed X Innovation Center, Biometrix, Biomillenia, BiomX, Bioniz Therapeutics, Bionpharma, BioPep, Biophage Pharma, BiopharmX, Bioqube Ventures, BiosanaPharma, Bioskin, Biosolution, BioStem Technologies, Biosynthetic Technologies, BirchBioMed, Bloomage BioTechnology, BMG Pharmaceuticals, Boehringer Ingelheim, Bone Medical, Boragen, Boston Pharmaceuticals, Boston Topicals, Botanix Pharmaceuticals, BoyaLife, Bpifrance, Brickell Biotech, Brigham and Women's Hospital, Bright Future Pharmaceutical Lab, Brown University, Bruin Biometrics, BSN Medical, Buffalo Supply, Cadila Pharmaceuticals, CALECIM Cosmeceuticals, Camargo Pharmaceutical Services, Can-Fite BioPharma, CANbridge Pharmaceuticals, Candela, CannaSkin, Cannassure Therapeutics, Cannaworx, CanniMed Therapeutics, Canopy Growth, Cap Alter Pharma, Capital Laser and Skin Care, Cara Therapeutics, CARB-X, Cardiome Pharma, Cardiovascular Systems, CarePICS, Carestream Health, Case Western Reserve University, Cassiopea, Castle Creek Biosciences, Celgene, Celleration, CellMark Medical, Cell Mogrify, Celularity, Certara, Ceva Sante Animale, Charite-Universitatsmedizin, Chelexa Biosciences, Chemipal, Chemstar, Children's Hospital Boston, China-Israel Biological Technology, China National Biotech Group (CNBG), Chong Kun Dang, Chongqing Jingdong Pharmaceutical, Chromaderm, Chromogenex Technologies, Chugai Pharmaceutical, Cilag AG, Cipher Pharmaceuticals, Cipla, Circadia, CIVCO Radiotherapy, CJ CheilJedang, Clarify Medical, Clinuvel Pharmaceuticals, CMS Medical, Codex Beauty, Collagen Solutions LLC, Collplant, Columbia University Medical Center, Contem 1G, ConvaTec, Cook Biotech, Cooper-Vemedia, Corza Health, Cosmotec, Costa Brazil, Covaleo, Covalon Technologies, Creabilis Therapeutics, Crescita Therapeutics, CROMA Pharma, Cronos Group, Crown Bioscience, Crown Laboratories, Cryolife, Cumberland Pharmaceuticals, CURE Pharmaceutical, Curetis, Curzion Pharmaceuticals, Cutanea Life Sciences, Cutia Therapeutics, Cynata Therapeutics, Cytori Therapeutics, CytoSorbents, Dabur, Dalhousie University, Daniel Alain Life Science, DASH Analytics, Daxor, Dechra Pharmaceuticals, Denali Therapeutics, Department of Defence, Department of Defense, Department of Veterans Affairs, DermaConcepts, DERMAdoctor, Dermala, DermapenWorld, Dermasilk, Dermata Therapeutics, Dermavant Sciences, DermBiont, Dermelix Biotherapeutics, Dermira, DermOQ, Dermpath Diagnostics, DermTech, Devonian Health Group, Digital Diagnostics, Dignitana, Dinaco, Diplomat, Dong-A ST, Dow Pharmaceutical Sciences, Dr. Reddy's Laboratories, Dr. U Devices, Draper Laboratories, Dr Bragi Company, Dr Kerklaan Therapeutics, DS Biopharma, DS Healthcare, DSM Nutritional Products, Ducere Pharma, Dyamed Biotech, Dynamic Blending, Dynasil, E-QURE, Easton Pharmaceuticals, EB Research Foundation, EB Research Partnership, Eccrine Systems, Eclipse Aesthetics, ECMOHO, Edesa Biotech, Egis, Eirion Therapeutics, Eisai, eKare, Ekpac Healthcare, Elanix Biotechnologies, Elektrofi, Elev8 Brands, Elevai Labs, Eligo Bioscience, Eli Lilly, Ember Therapeutics, EMC, Emmaus Life Sciences, Emollivet, Emory University, Emphysys, EMS, Enaltus, Encore Dermatology, Encore Medical, Endo International, Enteris Biopharma, Enzymatica, Epicore Biosystems, EPI Health, EQT, Equillium, Er-Kim, Espada Dermatology, EspeRare Foundation, Essity, Estee Lauder, Ethicon Endo-Surgery, Eureka Eurostars, Eurofins Scientific, European Wellness Biomedical Group, Eve & Co, Evolve BioSystems, Evommune, Ewopharma, ExCEEd Orphan, Excelra, Exicure, Expanscience, EZbra Advanced Wound Care, Fagron, Farco Pharma, FarmaMondo Group, Felix Biotechnology, Fillmed, First Horizon Pharmaceuticals, FirstString Research, Fission Labs LATAM, Flowerkist, Foamix Pharmaceuticals, Follicum AB, FormaTK Systems, Forte Biosciences, Fougera Pharmaceuticals, Frost Pharma, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Fuse Medical, Galapagos, Galderma, Gale Force Aesthetics, Gebro Pharma, Gecko Biomedical, Geisel School of Medicine at Dartmouth, Gel4Med, Gene Biotherapeutics, Genentech, GenesisCare, Genfa Medica, George Washington University, Ghassan Aboud Group, GHD GesundHeits, Givaudan, GlaxoSmithKline, GL Brands, GlobalMed, GPC Systems, Grove Collaborative, Grunenthal, Grupo Ferrer, GtreeBNT, Guangzhou Xiangxue Pharmaceutical, Gunze, Guthy-Renker, H2-Pharma, Hairmore Group, Happify Health, Harmony Hemp, Harvard Medical School, Hawkeye Therapeutics, Healiant, Helsinn Healthcare, HemCon Medical Technologies, Hemostasis, Henry M. Jackson Foundation, Henry Schein, Herbs Of Kedem, Heumann Pharma Generics, High Beauty, Hill Dermaceuticals, Histapharm, Histogen, HitGen, Hollister Biosciences, Hope Medicine, Horizon Therapeutics, Hoth Therapeutics, Houston Methodist Research Institute, HS Pharmaceuticals, Huapont Pharma, Huons, Hydrofera, Hyloris Pharmaceuticals, Iagnosis, Icahn School of Medicine at Mount Sinai, Ice + Jam, Ichnos Sciences, Ideal Medical Solutions, IDEAYA Biosciences, iFyber, IlmixGroup, ImaBiotech, Imbed Bio, IME Medical Electrospinning, IMIDomics, Immune Pharmaceuticals, Immunomic, Indipharm, Induce Biologics, Infinivive, Innate Biologics, Innovate UK, Innovation Skane, Innovative Cellular Therapeutics, Innovent Biologics, Innovus Pharmaceuticals, Inova Diagnostics, Intalere, Intas Pharmaceuticals, INTEGA Skin Sciences, Integra LifeSciences, Integumen, Intermountain Healthcare, Interpolymer/Zschimmer & Schwarz, Intralytix, IQVIA, iS Clinical, ISDIN, Isoprene Pharmaceuticals, Israeli National Authority for Technological Innovation, Jackson Laboratory, James Cook University, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Therapeutics, Japan Tobacco, JCR Pharmaceuticals, Jeune, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Joerns Healthcare, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Journey Medical, JT Pharmaceuticals, Juntendo University, JuvenIL, Juyou Biotechnology, JW Pharmaceutical, Kaken Pharmaceutical, Kaleido Biosciences, Kane Biotech, Karo Pharma, Kavo Kerr Group, Keck School of Medicine of USC, Kent Imaging, Keraderm, Kerecis, King's College Hospital, Kiniksa Pharmaceuticals, Kleresca, Knight Therapeutics, KNOW Bio, Kramer Laboratories, Krystal Biotech, Kubota Vision, Kyocera, Kyongbo Pharm, Kyowa Hakko Kirin, Kythera Biopharmaceuticals, L&P Cosmetic, L'Oreal, Lannett, Laser Clinics Australia, Laser Lab Corp, Lautus Pharmaceuticals, Lead Pharma, Legacy Biotechnologies, Leiden University, Lenus Therapeutics, Leon-nanodrugs, LEO Pharma, LGC, LifeMax Laboratories, Ligand Pharmaceuticals, Lighthouse Strategies, LiLa Enterprise, Lipidor, LipoTrue, Loreal, Lovell Government Services, Lubrizol, Lumenis, Luminera, Lupin, Luqa Pharmaceuticals, Lygos, Lysando, MainPointe, Mallinckrodt Pharmaceuticals, Mamba Instruments, MannKind Biopharmaceuticals, Maplex Naturals, Maren Cosmetics, Maruho, Massachusetts General Hospital, Massachusetts Life Sciences Center, Massage Envy, Matawan Pharmaceuticals, MatriSys Bioscience, Maxhealth Medicine, Mayne Pharma, MC2 Therapeutics, McMaster University, MDS Pharma Services, Meabco, Med-Aesthetic Solutions, Medcura, Medela, Medical College of Wisconsin, Medicamat, Medimetriks, MediPharm Labs, Mediq, MediWound, Medline Industries, MedPharm, MedShape, Medshift, Medx, Medybloom, Medytox, Meiji Seika, MELA Sciences, MellingMedical, MEME, Menarini, Menlo Therapeutics, Merakris Therapeutics, Merck and Co, Merck KGaA, Merz, Mesoblast, Metalabs, Metaoptima Technology, Metrion Biosciences, Michelson Diagnostic, Michepro, Micreos, Microbio Shanghai, MicroCures, MiNDERA, Mintcare, Miravo Healthcare, Mirum Pharmaceuticals, Misonix, Mitsubishi Tanabe Pharma, Moberg Pharma, Modoc Research Services, MolecuLight, Molnlycke Health Care, Momenta Pharmaceuticals, Monash University, MoonLake Immunotherapeutics, MorphoSys, MSM-Medimpex, MT.DERM, MTF Biologics, Mundimed, Mundipharma, Musculoskeletal Transplant Foundation, MWMedical, MyBiotics Pharma, Mylan Pharmaceuticals, MyungMoon Bio, Nabriva Therapeutics, Nanning Xinzizhu Trading, NanoVibronix, NassifMD Dermaceuticals, National Eczema Association, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institutes of Health, National Psoriasis Foundation, National Research Council Canada, National Research Council of Canada, National Science Foundation, Nationwide Laboratory Services, Neograft Technologies, NEO Tech, Neovacs, Neptune Wellness Solutions, Nestle, Net Health Systems, Neumedicines, NewSurg, New York University, New York University School of Medicine, Nexcure Pharma, NexGen Medical Systems, Nextmune, Nikkol, No BS Skincare, Nordic Pharma Group, North Carolina State University, Northwestern University, NovaBay Pharmaceuticals, Novan, Novan Therapeutics, Novartis, Novation, Novelty Nobility, Now Biopharma, Nuevolution, NuGene International, NuMedii, Nuo Therapeutics, Nutech Medical, Nutriband, Nuvothera, Oakrum Pharma, Obagi Cosmeceuticals, Obagi Medical Products, Office of Naval Research, Olaregen Therapeutix, Olika, OliX Pharmaceuticals, OncoBeta, Oncodesign, Oneness Biotech, ON Light Sciences, OptiBiotix, Or-Genix Therapeutics, Orca Pharmaceuticals, Orchard Therapeutics, Organogenesis, Organovo, Organ Technologies, ORIG3N, Origimm Biotechnology, Orphan Europe, Orpharm, Osiris Therapeutics, Otsuka, Ovation Science, OWC Pharmaceutical Research, Padagis, Palisade Bio, Palobiofarma, Palvella Therapeutics, Paratek Pharmaceuticals, Particle Sciences, PathogenDx, Patient-Centered Outcomes Research Institute (PCORI),, PCG Clinical Services, PDL BioPharma, Pediatric Dermatology Research Alliance, PellePharm, Pelle Ventures, Perrigo, Perry Baromedical, Peterson's Lab, Pfizer, Pharmacyna, PharmaResearch Products, Pharming Group, Phase Holographic Imaging, Phosphagenics, PhotoMedex, Phyto Tech, Piedmont Pharmaceuticals, Pierre Fabre, Pierre Fabre Dermatologie, Piqur Therapeutics, Plyzer Technologies, Podimetrics, PolarityTE, Pollogen, Poly Group, Popit, Portola Pharmaceuticals, Premier Inc, Prescient Surgical, Prestium Pharma, Prime Therapeutics, Prism Medical Products, Promius Pharma, Promore Pharma, Proscia, Protagen, Proya Cosmetics, Psilocin Pharma, Pura Naturals, Purdue Pharma, PureKana, Pure Med Farma, Purnovate, Pyramid Biosciences, Queensland University of Technology, Quest Products, Quoin Pharmaceuticals, RAHN, Ra Medical Systems, Randob Labs, Rapid Dose Therapeutics, Rational Surgical Solutions, Realm Therapeutics, Recipharm, Reckitt Benckiser, Red One Medical, Reedy Creek Investments, Regenerative Biologics, Regenerative Medicine of China, Regenerative Medicine of Latin America, Regenicin, Regis Technologies, ReLeaf Europe, Relief Therapeutics, Relife, Renovacare, Repertoire Immune Medicines, Replicel Life Sciences, Repurpose.AI, Resilia Pharmaceuticals, Restorix Health, Revance Therapeutics, Revive Therapeutics, Rev Pharma, Rigel Pharmaceuticals, RIKEN Yokohama Institute Omics Science Center, Rochal Industries, Roche, Rockefeller University, Rodan and Fields, Rohto Pharmaceutical, ROi (Resource Optimization & Innovation), Roivant Sciences, Royalty Pharma, Salus Medical, Samsung Bioepis, Samsung Biologics, Samumed, Sandoz, Sanmina, Sanofi, Santalis Pharmaceuticals, Sanuwave Health, Saraya, SastoMed, Sato Pharmaceutical, Scapa Healthcare, Schweiger Dermatology Group, SciBase, Science 37, Sciton, Sebacia, Second Genome, Sensus Healthcare, SenzaGen, Seqirus, SerenaGroup, Shanghai Corday Biotech, Shanghai Haohai Biological Technology, Shire Pharmaceuticals, Sienna Biopharmaceuticals, Signum Biosciences, Signum Dermalogix, Simris Biomimetics, Sinclair IS Pharma, Sincopharm, Sinopharm, Sinovant Sciences, Sirona Biochem, sk:n, SkinBiotix, Skincential Sciences, Skin Products, SkinScience Labs, SkinSciPac, Skinvisible, SMG Pharmaceuticals, Smith & Nephew, Sol-Gel, Soliton, Solomomo, Soluble Systems, Sonoma Pharmaceuticals, Sosei Heptares, Southmedic, Southwest Transplant Alliance, Spartan Medical, Spear Pharmaceuticals, Specialty Therapeutics PC, Spenta, Spherix, Spiracur, Springs Rejuvenation, Squalan Natural Health, Sternlaser Medical Aesthetics Solutions, Stiefel Laboratories, STRATA Skin Sciences, Stratatech, Stratpharma, Summit Pharmaceuticals / Alliance Labs, Sun Capital Partners, Sundaily, Suneva Medical, Sun Pharmaceutical, Surrozen, SutroVax, Swedish Bactiguard, Swift Medical, Swiss Institute of Allergy and Asthma Research, Swixx Biopharma, SWK Funding, Swysh, SYnergy Medsales, Syneron Medical, Systagenix Wound Management, Takeda Pharmaceutical, Tauriga Sciences, Taxus Cardium Pharmaceuticals, Teb Sanaat Lotus, Tec-Pharm, Tec-Pharma, TechCare, Technion Research and Development Foundation, TekCyte, Telemedicine Solutions, Terumo Cardiovascular Systems, TFS Corporation, The HydraFacial Company, The Innovation Fund, TheraLight, Theravant, TheraVida, ThermiGen, Thirona Bio, Thomas Jefferson University, Thought Leadership & Innovation Foundation, Timber Pharmaceuticals, Tissue Analytics, Tissue Regenix, Tissue Regenix Group, Titan Pharmaceuticals, Tocagen, Torii Pharmaceutical, Triage Technologies, Tricol International, Trinnovations, TRX Wound Care, Tulane University, TWi Biotechnology, TWi Pharmaceuticals, Tyris Therapeutics, uBiome, UCB, Uluru, Uni-Bio Science, Uniformed Services University of the Health Sciences, UNION Therapeutics, Univar, University of Alabama at Birmingham, University of Barcelona, University of British Columbia, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Los Angeles, University of California San Francisco, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Dundee, University Of Huddersfield, University of Manchester, University of Maryland Baltimore, University of Massachusetts, University of Michigan, University of New Mexico, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of South Australia, University of Virginia, University of Washington, University of Wisconsin, Upside Biotechnologies, Urgo Laboratories, USANA Health Science, US Army, US Army Institute of Surgical Research (USAISR), US Army Medical Research and Material Command, US Navy, Valeant Pharmaceuticals, ValenzaBio, Vasomune Therapeutics, Velocity Fund Partners, Venturis Therapeutics, Vericel, Verily, Verrica Pharmaceuticals, Veterans Medical Distributors, VHA, ViaDerma, Victoria University, VidaCeuticals Health Products, Vifor Pharma, ViroXis, VisionQuest Biomedical, Visualant, VisualDx, Vitae Pharmaceuticals, Vitro Biopharma, Vitruvias Therapeutics, Vizient, Vogue, Vomaris Innovations, Voronoi, VYNE Therapeutics, Warmuth Institute of Dermatology, Wearifi, Weihai Weigao Medical Devices, Weill Cornell Medical College, Wellness Center USA, WellSpring Pharmaceutical, West Dermatology, Winhealth Pharma Group, Wistar Institute, Wockhardt, Worcester Polytechnic Institute (WPI), Worldwide Clinical Trials, Wound Care Advantage, Wuhan Miracle Laser Systems, WuXi Biologics, X-chem, Xbiome, XBiotech, Xcede Technologies, Xcelerate Solutions, XCellR8, Xoma, Xycrobe Therapeutics, Yale School of Medicine, Yissum Research Development, YOFOTO (China) Health Industry, YuYang DNU, YuYu Pharma, Z-Medical, ZappRx, Zenoaq, ZetrOZ, Zhittya Genesis Medicine, Ziarco Pharma, Zikad International Aesthetics Supplier, Zuellig Pharma China, Zymetech, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.